메뉴 건너뛰기




Volumn 23, Issue 27, 2005, Pages 6807-6809

The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer [16]

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT;

EID: 27244432204     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.3952     Document Type: Letter
Times cited : (3)

References (5)
  • 1
    • 20044382779 scopus 로고    scopus 로고
    • American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for post-menopausal women with hormone receptor positive breast cancer: Status
    • Winer EP, Hudis C, Burstein H, et al: American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for post-menopausal women with hormone receptor positive breast cancer: Status report 2004. J Clin Oncol 23:619-630, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 619-630
    • Winer, E.P.1    Hudis, C.2    Burstein, H.3
  • 2
    • 11444251764 scopus 로고    scopus 로고
    • Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
    • The ATAC Trials Group
    • The ATAC Trials Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
    • (2005) Lancet , vol.365 , pp. 60-62
  • 3
    • 21044435630 scopus 로고    scopus 로고
    • The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis
    • San Antonio, TX, December 8-11
    • Coombes RC, Hall E, Snowden CF, et al: The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. 27th San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004
    • (2004) 27th San Antonio Breast Cancer Symposium
    • Coombes, R.C.1    Hall, E.2    Snowden, C.F.3
  • 4
    • 84871474535 scopus 로고    scopus 로고
    • Dowsett M: Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 82 (suppl 1; abstr 4 S7), 2003
    • Dowsett M: Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 82 (suppl 1; abstr 4 S7), 2003
  • 5
    • 84871473615 scopus 로고    scopus 로고
    • Baum M. ATAC Update: Are there now sufficient data to replace tamoxifen with anastrozole as first line therapy for hormone receptor positive postmenopausal breast cancer? 27th San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004
    • Baum M. ATAC Update: Are there now sufficient data to replace tamoxifen with anastrozole as first line therapy for hormone receptor positive postmenopausal breast cancer? 27th San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.